Yadalam Adithya K, Chaudagar Kiranj, Mumme Hope, Bhasin Manoj, Talekar Ganesh R, Waller Edmund K, Lesinski Gregory B, Patel Sagar A, Mandawat Anant
Department of Medicine, Emory University School of Medicine, Division of Cardiology, Atlanta, GA.
Department of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute of Emory University, Atlanta, GA.
Clin Genitourin Cancer. 2025 Aug;23(4):102358. doi: 10.1016/j.clgc.2025.102358. Epub 2025 Apr 14.
Androgen deprivation therapy (ADT) is associated with increased cardiovascular disease (CVD) risk in prostate cancer (PCa). We hypothesized that ADT would increase circulating adipocytokine levels linked to CVD risk and mortality.
Adipocytokine levels were measured in men with localized PCa (N=10) pre- and post-6 months of leuprolide therapy.
CCL2, KIM-1, leptin, osteopontin, and TIMP-1 levels significantly increased post-leuprolide (P-values<0.05) relative to baseline, but no changes were observed in IL-1β, IL-6, IFN-γ and TNF-α.
Leuprolide is associated with upregulation of certain adipocytokines in localized PCa patients, which may contribute to the ADT-associated increase in CVD mortality in PCa.
雄激素剥夺疗法（ADT）与前列腺癌（PCa）患者心血管疾病（CVD）风险增加相关。我们推测ADT会增加与CVD风险和死亡率相关的循环脂肪细胞因子水平。
对10例局限性PCa男性患者在接受亮丙瑞林治疗前及治疗6个月后测量脂肪细胞因子水平。
与基线相比，亮丙瑞林治疗后CCL2、KIM-1、瘦素、骨桥蛋白和TIMP-1水平显著升高（P值<0.05），但IL-1β、IL-6、IFN-γ和TNF-α未观察到变化。
亮丙瑞林与局限性PCa患者某些脂肪细胞因子的上调有关，这可能导致PCa中与ADT相关的CVD死亡率增加。
